Acadia Pharmaceuticals Inc. ACAD
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -22.91%
- 1 year
- -9.45%
- Open
- 20.88
- Prev close
- 20.76
- Mkt cap
- 3.53B
- Vol
- 1.14M
- Avg vol
- 1.87M
- EPS
- 2.23
- P/E
- 9.23
- Div yield
- 0.00%
More statistics
- Low
- 20.49
- High
- 21.01
- Forward P/E
- 22.43
- Beta
- 0.89
- Short ratio
- 3.81
- Inst. own
- 100.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 23.91
- 200-d avg
- 23.71
- 1y target
- 30.53
5D chart
Signals (113)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
3 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
4 days ago businesswire.com
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17,…
4 days ago zacks.com
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…
1 week ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
1 week ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…
1 week ago defenseworld.net
Needham & Company LLC Reaffirms Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Needham and Company LLC in a research note issued on Monday, Benzinga reports.…
-
1 week ago benzinga.com
Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target
Needham analyst Ami Fadia reiterates Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $35 price target.
2 weeks ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
2 weeks ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…
-
2 weeks ago benzinga.com
UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
2 weeks ago zacks.com
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
2 weeks ago defenseworld.net
Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)
C4 Therapeutics (NASDAQ: CCCC - Get Free Report) and ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the…
3 weeks ago zacks.com
4 CNS Drug Stocks Worth Watching This World Mental Health Day
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
3 weeks ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36
RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.
3 weeks ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
1 month ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…
1 month ago zacks.com
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
-
1 month ago benzinga.com
Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”
https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-allowance-of-u-s--patent-covering-weight-banded-dosing-of-trofinetide-extending-u-s--patent-protections-to-march-2041
1 month ago businesswire.com
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent…
1 month ago schaeffersresearch.com
3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI
Options bears are circling three stocks today, with Aemetis Inc (NASDAQ:AMTX), Acadia Pharmaceuticals Inc (NASDAQ:ACAD), and Resideo Technologies Inc (NYSE:REZI) all seeing puts handily outpace calls.
1 month ago zacks.com
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
-
1 month ago benzinga.com
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.
1 month ago benzinga.com
AMD To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday
Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings remained unchanged.
-
1 month ago benzinga.com
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.
-
1 month ago benzinga.com
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34
BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.
-
1 month ago benzinga.com
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.
-
1 month ago benzinga.com
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.
1 month ago benzinga.com
Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis
Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer’s psychosis and plans to move into Phase 3.
1 month ago benzinga.com
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
-
1 month ago benzinga.com
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target
Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $41 price target.
-
1 month ago benzinga.com
Acadia’s Remlifanserin Advances Toward Phase 3 In Alzheimer’s Psychosis Despite Narrow Miss On Primary Endpoint
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect--…
-
1 month ago benzinga.com
Acadia Pharmaceuticals Receives Preliminary Court Approval Of Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action
On August 24, 2026, the United States District Court for the Southern District of California (the "Court") preliminarily approved the settlement ("Settlement") of the stockholder derivative action
-
2 months ago benzinga.com
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.
-
2 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.
-
2 months ago benzinga.com
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.
-
2 months ago benzinga.com
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49
UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $45 to $49.
-
2 months ago benzinga.com
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.
-
2 months ago benzinga.com
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $39.
-
2 months ago benzinga.com
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25
Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $23 to $25.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37
RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $37.
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises the price target from $35 to $36.
-
2 months ago benzinga.com
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est
ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.
-
2 months ago benzinga.com
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.07 by 157.14 percent. This is a 12.5 percent increase over earnings…
-
3 months ago benzinga.com
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $34 to $36.
3 months ago benzinga.com
Robinhood To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts change outlook on top names. See all rating changes, including upgrades and downgrades, on analyst ratings page.
-
3 months ago benzinga.com
Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25
Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises the price target from $24 to $25.